Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxart Inc VXRT

Healthcare Biotechnology
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its... see more

Recent & Breaking News (NDAQ:VXRT)

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

GlobeNewswire March 27, 2024

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 20, 2024

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

GlobeNewswire March 14, 2024

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

GlobeNewswire March 7, 2024

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

GlobeNewswire March 6, 2024

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

GlobeNewswire February 5, 2024

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

GlobeNewswire January 19, 2024

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

GlobeNewswire January 16, 2024

Vaxart, Inc. Announces Management Change

GlobeNewswire January 16, 2024

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

GlobeNewswire December 21, 2023

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

GlobeNewswire November 2, 2023

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

GlobeNewswire November 2, 2023

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

GlobeNewswire October 26, 2023

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

GlobeNewswire October 11, 2023

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

GlobeNewswire September 21, 2023

Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate

GlobeNewswire September 6, 2023

Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 3, 2023

Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3

GlobeNewswire July 27, 2023

Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate

GlobeNewswire July 6, 2023

Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement

GlobeNewswire June 26, 2023